Potential Medicare Part D Savings on Ophthalmic Generic Drugs

Overview of attention for article published in JAMA Ophthalmology, July 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 1003 X posts from 963 X users, with an upper bound of 11,783,552 followers.

This economic evaluation assesses potential Medicare Part D savings on ophthalmic generic drugs if discount coupon prices are used. https://t.co/rKCaFaXy8f https://t.co/5prFMCBN2g

RT @mcuban: This is amazing. @costplusdrugs could save taxpayers $140m for just a small number of drugs. We are ready !

RT @dcollet95: Medicare Part D is overpaying by more than $140 million for ophthalmic generics compared to prices offered by @costplusdrugs…

RT @dcollet95: Medicare Part D is overpaying by more than $140 million for ophthalmic generics compared to prices offered by @costplusdrugs…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 999 additional X posts.